DOPE-ICU Site Master File

Site Master File

Table of Content (1 through 12)

Please see LOG for latest up-loads of new documents and/or new versions of documents in Trial Master File

1) Protocol and trial synopsis

a) Approved protocol

b) Approved amendments

c) Trial synopsis

d) Front page of protocol signed

2) eCRF (for instruction, please see 8.a.iii.)

3) Trial participants

a) Delegation- and signature-log (in Danish)

b) Training log (Danish) 

4) Approvals and correspondence

a) The Committee on Health Research Ethics in the North Denmark Region (in Danish)

b) Local approvals (site specific)

c) Annual Safety Report

5) Collaboration agreement

a) Collaboration agreement between Sponsor and site 

b) Approval from head of department (in Danish)

c) Other relevant contracts (site specific)

6) Information to participants

a) Trial information to trial guardian, relatives and patient (in Danish).

b) Consent form to trial guardian, relatives and patient (in Danish).

c) The rights of the patient in clinical research (in Danish)

7) Co-enrolment and sub-studies

a) Co-enrolment Form (with access to co-enrolment list)

b) Sub-study proposal form

8) Trial documents

a) Trial instructions

i) Eligibility (Danish)

ii) Screening and randomisation

iii) Instructions for the eCRF 

iv) SAE

v) SOP for escape procedures (Danish)

vi) Instructions for obtaining consent (Danish)

b) Pocket cards, documents for a notice board in the department

i) Inclusion and exclusion criteria for notice board

ii) Trial synopsis for notice board

iii) Pocket cards (Danish)

iv) Leaflet for clinical staff (Danish) 

v) Sign for bed

c) Educational material (power point presentations)

i) Initiation for investigators (slides) and for primary trial personnel (slides)

9) Communication

a) Contact details – Management Committee

b) Contact details – participating sites

c) Note to file send to Sponsor (template)

d) Note to file received from Sponsor (template)

e) Other correspondences between Sponsor and site(s) (site specific)

f) Newsletters

g) Correspondence to primary investigators and primary trial personnel (e-mails)

10) Serious adverse events and suspected unexpected serious adverse reactions

11) Trial completion

12) Appendices